Background:Herpes zoster (HZ) poses significant risks to immunocompromised individuals, particularly cancer patients receiving systemic therapies. The recombinant zoster vaccine (RZV, Shingrix®) provides strong and durable protection against HZ and its complications. Nevertheless, vaccination coverage remains low, mainly due to limited awareness among patients and healthcare providers and logistical barriers to vaccine access and delivery.Materials and Methods:We conducted a single-center quality improvement (QI) project to enhance RZV uptake among oncology outpatients receiving systemic therapy. Following the Plan–Do–Study–Act (PDSA) model, baseline HZ vaccination coverage was assessed, and an in-house vaccination campaign was implemented. Vaccination rates were monitored every two months over a 14-month period.Results:At baseline, only 5.4% (24/446) of patients had received RZV. After 14 months, 365 patients were evaluated for vaccination: 200 (55%) were vaccinated, 134 (37%) were ineligible, and 31 (8%) refused RZV. The overall vaccination rate increased from 5.4% to 44%. Reported adverse events were mild and primarily local reactions, confirming the vaccine’s favorable safety profile in this population.Conclusions:This real-world QI initiative demonstrates that an in-house vaccination strategy embedded within oncology services can substantially improve RZV coverage and patient engagement. The approach highlights the key role of oncology teams in leading preventive interventions for immunocompromised patients. By integrating vaccination into routine cancer care, institutions can overcome traditional organizational barriers and align with current ASCO and ESMO recommendations for comprehensive patient protection.
背景：带状疱疹对免疫功能低下人群构成显著风险，尤其是接受全身性治疗的癌症患者。重组带状疱疹疫苗（RZV，商品名Shingrix®）能提供强效持久的保护，预防带状疱疹及其并发症。然而，疫苗接种覆盖率仍然较低，主要原因是患者和医疗提供者认知有限，以及疫苗获取和接种存在后勤障碍。 材料与方法：我们开展了一项单中心质量改进项目，旨在提高接受全身性治疗的肿瘤门诊患者的RZV接种率。遵循“计划-实施-研究-行动”模型，评估了基线带状疱疹疫苗接种覆盖率，并实施了院内疫苗接种活动。在14个月期间，每两个月监测一次疫苗接种率。 结果：基线时，仅有5.4%（24/446）的患者接种了RZV。14个月后，对365名患者进行了疫苗接种评估：200名（55%）已接种，134名（37%）不符合接种条件，31名（8%）拒绝接种RZV。总体疫苗接种率从5.4%提高至44%。报告的不良事件轻微，主要为局部反应，证实了该疫苗在此人群中的良好安全性。 结论：这项真实世界的质量改进项目表明，嵌入肿瘤服务的院内疫苗接种策略可显著提高RZV覆盖率和患者参与度。该方法凸显了肿瘤团队在领导免疫功能低下患者预防性干预中的关键作用。通过将疫苗接种整合到常规癌症护理中，医疗机构可以克服传统的组织障碍，并与当前美国临床肿瘤学会和欧洲肿瘤内科学会关于全面保护患者的建议保持一致。
肿瘤(癌症)患者之家